עוד מחקר מצאתי בגוגל
ומצאתי עוד משהו. מה זה
IVIg ? אבקש עזרה בתירגום מה
IVIg ? מה זה
antibodies ?
What is IVIg?
IVIg stands for IntraVenous Immunoglobulin. It is a product of human blood that is derived from the plasma of thousands of healthy volunteers.
IVIg contains
antibodies, which are the proteins that help protect the body against disease. Why is
IVIg being studied as a treatment for Alzheimer's? It was recently discovered that
IVIg contains
antibodies that bind to beta amyloid (A). A is a protein that many scientists believe is important in causing Alzheimer's.
IVIg may help to promote the clearance of A from the brain and block A's toxic effects on brain cells. Is
IVIg a new treatment?
IVIg was originally approved by the U.S. Food and Drug Administration for treating immune disorders in children and has been available for more than 30 years.
IVIg is FDA-approved for the treatment of patients with primary immunodeficiencies, immune thrombocytopenic purpura (ITP), B-cell chronic lymphocyctic leukemia (CLL), Kawasaki syndrome, and immunodeficiency associated with pediatric HIV and bone marrow transplantation. Neurologists also use
IVIg in the treatment of multiple sclerosis and motor neuropathy, though
IVIg is not approved for these conditions. It is not currently approved to treat Alzheimer's disease, but is under study for that purpose. How is
IVIg treatment given?
IVIg is administered by an infusion into a vein, a process that typically takes several hours. It is believed that infusions have to be carried out at least once or twice a month in Alzheimer's patients. Is
IVIg safe? Several hundred thousand persons have received
IVIg over the years, and it is generally well-tolerated. There may be added risks to its use in elderly individuals with Alzheimer's, but many older persons have received
IVIg without difficulty. Because it is derived from human blood,
IVIg carries with it a very small risk of communicable diseases such as Hepatitis and HIV. However, in the United States there have been no documented cases of transmission of these diseases by
IVIg over the past 10 years. Other possible risks relating to use of
IVIg include kidney failure, stroke, lung problems, heart failure, allergic reactions and other problems. The likelihood of these complications occurring can be reduced by screening out persons who have known risk factors and administering the
IVIg in modified forms.
